Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.58 |
| ▸ | CES1 | P23141 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028977 | 0.98 | CES2 (0.61) | CES2CES1ALDH1A1TSHR | |
| SCHEMBL1304772 | 0.92 | — | — | |
| SCHEMBL5423233 | 0.83 | CES2 (0.56) | CES2CES1ALDH1A1TSHRAKR1B1 | |
| SCHEMBL1037738 | 0.81 | CES2 (0.59) | CES2CES1ALDH1A1TSHRMEN1 | |
| SCHEMBL10715049 | 0.81 | CES2 (0.54) | CES2CES1ALDH1A1TSHRAKR1B1 | |
| SCHEMBL10693849 | 0.81 | CES2 (0.59) | CES2CES1ALDH1A1TSHRMEN1 | |
| SCHEMBL11468377 | 0.81 | CES2 (0.59) | CES2CES1ALDH1A1TSHRMEN1 | |
| SCHEMBL11459441 | 0.81 | CES2 (0.59) | CES2CES1ALDH1A1TSHRMEN1 | |
| SCHEMBL11801715 | 0.79 | CES2 (0.52) | CES2CES1ALDH1A1TSHRAKR1B1 | |
| SCHEMBL10646004 | 0.79 | CES2 (0.52) | CES2CES1ALDH1A1TSHRAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112174966-B | New method for preparing piroxicam hydrochloride | 重庆圣华曦药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112174966-A | Novel method for preparing piricaconide hydrochloride | 重庆圣华曦药业股份有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-8664428-B2 | Method for producing (2,4-dimethylbiphenyl-3-yl)acetic acids, the esters thereof and intermediate compounds | BAYER CROPSCIENCE AG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | BAYER CROPSCIENCE AG (DE) | 2012-05-10 | — | — | US | disclosed |
| CN-102227261-A | Hydrogenation of ester, ketone or aldehyde groups with ruthenium complexes having di-amine and phosphorous-nitrogen bidentate ligand | FIRMENICH & CIE | 2011-10-26 | — | — | CN | disclosed |
| EP-2370207-A1 | HYDROGENATION OF ESTER, KETONE OR ALDEHYDE GROUPS WITH RUTHENIUM COMPLEXES HAVING A DI-AMINE AND A PHOSPHOROUS-NITROGEN BIDENTATE LIGAND | Firmenich S.A. (CH) | 2011-10-05 | — | — | EP | disclosed |
| CN-102164673-A | Hydrogenation of esters or carbonyl groups with phosphino-oxide based ruthenium complexes | FIRMENICH & CIE | 2011-08-24 | — | — | CN | disclosed |
| US-20110190523-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH PHOSPHINO-OXIDE BASED RUTHENIUM COMPLEXES | FIRMENICH SA (CH) | 2011-08-04 | — | — | US | disclosed |
| EP-2344276-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH PHOSPHINO-OXIDE BASED RUTHENIUM COMPLEXES | Firmenich S.A. (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010061350-A1 | HYDROGENATION OF ESTER, KETONE OR ALDEHYDE GROUPS WITH RUTHENIUM COMPLEXES HAVING A DI-AMINE AND A PHOSPHOROUS-NITROGEN BIDENTATE LIGAND | FIRMENICH SA (CH) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010038209-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH PHOSPHINO-OXIDE BASED RUTHENIUM COMPLEXES | FIRMENICH SA (CH) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116118-A1 | Method for Producing (2,4-Dimethylbiphenyl-3-yl)Acetic Acids, the Esters Thereof and Intermediate Compounds | DDC, DDT, PAH | CES2 1393/4885CES1 2252/4885ALDH1A1 40/4885 |
| US-20110190523-A1 | HYDROGENATION OF ESTERS OR CARBONYL GROUPS WITH PHOSPHINO-OXIDE BASED RUTHENIUM COMPLEXES | PNN, ADH5, NCL | CES2 697/4885CES1 1043/4885ALDH1A1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.